HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

J Infect Dis. 2022 Jan 5;225(1):116-120. doi: 10.1093/infdis/jiab336.

Abstract

We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6-7.9) and 4.5 (IQR, 3.5-5.0) log10 copies/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6-10.4) and 24 weeks in BP (95% CI, 14.1-33.9).

Keywords: HIV-1; dolutegravir; drug concentration; primary HIV infection; seminal plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV-1 / genetics*
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Oxazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Pyridones / therapeutic use*
  • RNA, Viral / genetics
  • Semen / virology*
  • Viral Load

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • RNA, Viral
  • dolutegravir